Sofosbuvir reduces transplant rate in HCV patients
Sofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
Patients infected with hepatitis C virus (HCV) who have decompensated liver disease should be treated with a sofosbuvir-based regimen, according to a new study.
Direct-acting antiviral agents (DAAs) have transformed the treatment of chronic HCV infection. However, the impact of treating with DAAs versus no treatment on key outcomes in patients with decompensated cirrhosis has not been well defined.
“This is the first study to demonstrate the impact of DAAs in this sick population in the context of multiple clinical trials and comparing to a group of control patients who were not treated,” senior author Michael Charlton, MD, associate director of Intermountain Medical Center Transplant Program in Salt Lake City, Utah, told Medical Economics.
The researchers presented the results at the